Printer Friendly

Cook's Zenith Branch Endovascular Graft Receives CE Mark Approval.

New Device is First-of-its-Kind for Internal Iliac Aneurysm Repair Without Blocking Blood Flow Through the Iliac Artery

BLOOMINGTON, Ind. -- William Cook Australia, a global leader in endovascular therapy products, has taken another major step forward in the treatment of complex aortic aneurysms. The Zenith Branch Endovascular Graft, a new product using Cook's groundbreaking Zenith anchored endograft technology, has received CE Marking approval in Europe, allowing its distribution in the European Union and other countries that recognize the CE Mark.

The Zenith Branch Graft is the world's only endovascular graft specifically designed to treat aortic aneurysms while preserving blood flow to the internal iliac artery. This milestone is a further example of Cook's unmatched commitment to providing physicians with the industry's only comprehensive set of endografts and accessories for treating aneurysms and other disorders along the entire length of the aorta.

"As many as one in five patients with abdominal aortic aneurysms also present with iliac aneurysms. The Zenith Branch Endovascular Graft brings cutting-edge clinical developments to a cohort of patients who may not have otherwise been candidates for iliac aneurysm repair," said Barry Thomas, global leader of Cook's endovascular therapy products division. "We expect the Zenith Branch Graft to provide an important clinical option to European physicians treating aneurysm patients who cannot be treated using standard, off-the-shelf endograft components. We hope to make this exciting technology available in the U.S. in the very near future."

Used in conjunction with the proven Zenith AAA Graft and Zenith Iliac Leg Grafts, the Zenith branch graft allows treatment of the iliac aneurysm without the need for iliac embolization. By preserving the blood flow to the iliac artery, the graft reduces the potential for blockage-related problems.

The Zenith Branch Endovascular Graft is an investigational device not approved for sale in the U.S.

About Cook

The world's largest privately held manufacturer of medical devices with international headquarters in Bloomington, Ind., COOK[R] (www.cookmedical.com) is a leading designer, manufacturer and global distributor of minimally invasive medical device technology for diagnostic and therapeutic procedures. Since its founding in 1963, Cook has created innovative technologies for drug-eluting and bare metal stents, aortic and vascular endografts, catheters, wire guides, introducer needles and sheaths, embolization coils, medical biomaterials and contract manufacturing of biopharmaceuticals, vena cava filters and other minimally invasive medical devices for radiology, cardiology, urology and women's health, critical care medicine, surgery, gastroenterology, bone access and endovascular therapies.
COPYRIGHT 2006 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Oct 10, 2006
Words:403
Previous Article:Mel Webster Joins Aquarius Advisers.
Next Article:Marvel to Report Q3 Results and Host Webcast Monday, November 6TH AT 9:00 a.m. EST.
Topics:


Related Articles
COHESION GETS CE MARK FOR COSEAL SURGICAL SEALANT.
Terumo Announces Acquisition of MicroVention; Acquisition to Facilitate Terumo's Entry into the High Growth Market of Catheter-Based Technologies for...
COOK Applauds and Confirms Data from the Journal of Vascular Surgery Reporting High Success Rates of Endovascular Aortic Repair; Data Reveals Even...
Cook Inc.'s Zenith(R) Fenestrated Workshop Promotes Endovascular Aortic Repair Throughout Canada.
Cook Inc.'s Zenith(R) Fenestrated Endograft Successfully Implanted in 1,000th Case to Treat Complex Abdominal Aortic Aneurysms; Landmark Case...
Cook Announces Completion of the 100th Zenith Renu(R) Graft Registry Case To Treat AAA Patients with Migrating Aortic Endografts.
Cook Incorporated Completes Enrollment of Patients in STARZ-TX2 Trial; Study Results on Zenith(R) TX2(TM) Endovascular Graft for Thoracic Aortic...
Cook First to Bring Endovascular AAA Repair To Japan; Immediate Leadership Position Reinforced by Strong Regional Demand for Minimally Invasive...
Cook Incorporated Receives FDA Approval for Breakthrough Endovascular Graft.
Cook Reports Preliminary Reimbursement for Endovascular AAA Repair in Japan.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters